在急性缺血性中风出院后,老年患者中的 gabapentin 治疗模式
Shuo Sun1, Maria A Donahue2, Rebeka Bustamante Rocha2,3
1Department of Population Health Sciences, Weill Cornell Medicine, New York, New York.
medRxiv : the preprint server for health sciences
|October 3, 2025
概括
在因急性缺血性中风住院的老年人中,一半的患者在开始药物治疗后一年内保持了 gabapentin 覆盖范围. 这项研究检查了这个患者群体中 gabapentin 处方模式.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 加巴丁通常被非标签处方用于治疗急性缺血性中风后的疼痛.
- 最佳的 gabapentin 处方做法,特别是非标签用途和持续时间,仍然不清楚.
研究的目的:
- 为了检查老年人加巴丁治疗模式,在急性缺血性中风出院后30天内开始服用药物.
- 描述药物治疗的持续时间,并确定不同的治疗模式.
主要方法:
- 这是一项回顾性观察性研究,该研究使用了2013-2021年期间因急性缺血性中风 (AIS) 住院的美国医疗保险受益人的20%随机样本.
- 一种新的潜伏类混合模型方法分析了在启动后12个月内覆盖日数 (PDC) 的时间变化比例.
- 80%的PDC值区分了高与低的药物覆盖率.
主要成果:
- 队列 (N=1,628) 包括65岁以上的患者;平均年龄76.4岁,60%为女性,76.5%为非西班牙裔白人.
- 确定了三种 gabapentin 治疗模式:快速低覆盖率 (在 2 个月内<80% PDC) 在 42.5%,逐渐下降覆盖率在 5.9%,高/稳定覆盖率 (在 12 个月内≥80% PDC) 在 51.6% 的患者.
- 超过一半 (51.6%) 的患者保持高且稳定的 gabapentin 覆盖至少一年.
结论:
- 大约一半的因急性缺血性中风住院的老年人,在出院后开始服用 gabapentin,保持了持续的药物治疗12个月或更长时间.
- 这些发现突出了这个人群中 gabapentin 坚持和覆盖时间的变化.
- 需要进一步的研究来优化对中风患者的 gabapentin 处方.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
632
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
632
Drug Dosing: Geriatric Patients
225
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
225
Pharmacodynamics in Geriatric Patients: Effects of Age
187
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
187
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Alzheimer's Disease: Treatment
822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822
Acute Coronary Syndrome IV: Interprofessional Care
219
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
219


